Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published online in The Lancet Infectious Diseases.
The results are significant as public health experts have long warned that the parasite responsible for most malaria cases, Plasmodium falciparum, is developing resistance to widely used treatments. New medications are needed to build up secondary defenses against drug-resistant strains of the parasite.
The drug, called AQ-13, was able to clear the parasite responsible for the disease within a week, matching the effectiveness of the most widely used treatment regimen.
“The potential long-term implications are bigger than one drug. The conceptual step here is that if you understand the resistance well enough, you may be actually be able to develop others as well.”
Dr. Donald Krogstad
“The clinical trial results are extraordinarily encouraging,” said Dr. Donald Krogstad, senior author and professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine. “Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well.”
Mosquitoes infected by a parasite spread malaria, causing more than 200 million illnesses across the globe and more than 400,000 deaths annually. For decades, chloroquine was used to treat malaria until Plasmodium falciparum developed resistance. Now, a drug combination — artemether and lumefantrine — is the primary treatment for malaria although resistance is also developing to the drug combination in some countries.
Researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that isn’t life threatening. Half were treated with AQ-13 and the other half received artemether and lumefantrine. Both drug groups had similar cure rates. However, five participants in AQ-13 group left the study or were lost to follow-up and two participants in the artemether/lumefantrine group had late treatment failures with recurrence of their original infections.
Researchers hope to expand testing of the drug to more participants, including women and children, before it can be widely recommended as a new treatment. Krogstad said that the same biotechnology that helped the team develop the new drug has also identified similar drugs that also hold promise against drug-resistant parasites.
The Latest on: Malaria
- Malaria No More India and Times Bridge launch a Google Assistant feature that will answer people’s queries on malariaon November 26, 2020 at 11:07 pm
Malaria No More India, with support from Times Bridge, launched the Malaria No More on Google Assistant today for Indians using android devices. To activate this feature, an android user can command ...
- Malaria Vaccines Market 2020 Research Study including Growth Factors, Types and Application to 2026on November 25, 2020 at 7:59 am
The malaria vaccines market is expected to reach USD 156.8 million by 2026 according to a new study published by Polaris Market Research.The market for malaria vaccines globally has been divided based ...
- 2020 Eureka Prizes go to a ‘milkshake for malaria’, ABC’s Coronacast and an energy-making sewerage systemon November 24, 2020 at 2:29 am
Seventeen prizes were awarded in this year's ceremony, recognising a diverse group of scientific minds devoted to solving key 21st century issues.
- After Battling Covid, Malaria And Dengue, Man Now Survives Deadly Snakebiteon November 23, 2020 at 4:50 am
After recovering from COVID-19, dengue and malaria, a man in India is currently recuperating from a potentially deadly snake bite. Ian Jones, a charity worker from Britain who has been living in India ...
- After Malaria And Covid, British Man Survives Cobra Bite In Indiaon November 21, 2020 at 7:34 am
A British charity worker who survived coronavirus, dengue and malaria was recovering after a potentially deadly snake bite in western India's Rajasthan state. Ian Jones was bitten by an Indian cobra ...
- Lancaster University to help control the spread of invasive malaria mosquitoon November 20, 2020 at 3:17 pm
Lancaster University is involved in a major research project which aims to control the spread of an invasive malaria mosquito in Sudan and Ethiopia.
- EU Malaria Fund: Sanaria receives substantial investment into its proprietary malaria platformon November 15, 2020 at 7:05 am
On the occasion of the Annual Meeting of the American Society of Tropical Medicine and Hygiene approximately 4,900 global health professionals representing academia, government, and the private sector ...
- Africa: How Can Countries Continue to Combat Malaria During a Pandemic?on November 10, 2020 at 4:00 pm
Malaria results in nearly half a million deaths globally every year, with about 90% of cases occurring in sub-Saharan Africa. Due to disruptions of the delivery of mosquito nets and anti-malarial ...
- As malaria season begins, COVID-19 complicates issueson November 6, 2020 at 11:04 pm
TWO of the nine global public health awareness days are associated with malaria: World Malaria Day, observed on April 25 and World Mosquito Day, which commemorates the discovery by Sir Ronald Ross ...
- Malaria test as simple as a bandageon November 1, 2020 at 4:00 pm
A test for malaria looks like a bandage, but can diagnose the disease in minutes without the need for medical expertise or specialized equipment. That's the idea behind a platform developed by ...
via Google News and Bing News